▁British 8.5859375
▁Bi 8.046875
ote 1.814453125
ch 0.12213134765625
▁Pl 6.47265625
c 2.451171875
, 2.71875
▁a 0.9326171875
▁ren 7.390625
owned 0.2193603515625
▁ph 3.6875
arma 0.024993896484375
ce 0.032501220703125
ut 0.00010013580322265625
ical 0.00045561790466308594
▁company 0.5302734375
, 0.87353515625
▁has 1.025390625
▁recently 2.859375
▁generated 8.0234375
▁considerable 5.328125
▁excitement 3.9453125
▁in 1.2998046875
▁the 0.11297607421875
▁medical 3.150390625
▁field 2.80078125
▁with 1.6748046875
▁its 0.828125
▁prom 4.37890625
ising 0.0021533966064453125
▁cancer 4.36328125
▁drug 1.537109375
, 1.0927734375
▁Mar 7.70703125
im 5.859375
ast 0.05401611328125
at 2.467632293701172e-05
. 0.263671875
▁Though 7.06640625
▁the 0.9873046875
▁drug 1.1884765625
▁displays 8.203125
▁significant 3.087890625
▁potential 1.0751953125
, 1.396484375
▁several 4.47265625
▁considerable 8.8203125
▁hur 2.294921875
d 8.547306060791016e-05
les 0.00024175643920898438
▁remain 1.4892578125
▁on 3.638671875
▁the 0.371337890625
▁path 0.88916015625
▁to 0.351806640625
▁block 8.6171875
b 0.0616455078125
uster 0.00994873046875
▁success 1.6796875
. 0.1932373046875
<0x0A> 0.91455078125
Mar 2.171875
im 0.0069580078125
ast 0.0010194778442382812
at 0.004940032958984375
, 1.7099609375
▁an 3.09375
▁innov 4.4453125
ative 0.01268768310546875
▁matrix 6.5546875
▁metal 0.02764892578125
lo 0.0010900497436523438
prote 0.06365966796875
in 0.05810546875
ase 0.0175628662109375
▁in 0.923828125
hib 0.00042891502380371094
itor 0.00659942626953125
, 0.413330078125
▁has 1.1298828125
▁shown 1.9990234375
▁remarkable 2.54296875
▁effic 1.84765625
acy 0.00015842914581298828
▁in 0.1739501953125
▁pre 2.263671875
cl 0.43798828125
in 2.1576881408691406e-05
ical 0.00044417381286621094
▁and 1.9404296875
▁early 1.8603515625
- 1.2060546875
stage 0.170166015625
▁clin 0.1634521484375
ical 0.00025010108947753906
▁tri 0.15087890625
als 3.337860107421875e-05
, 1.6083984375
▁potentially 4.8984375
▁revolution 2.1640625
izing 0.04547119140625
▁cancer 2.17578125
▁treatment 0.1383056640625
. 0.1685791015625
▁By 4.4375
▁in 0.779296875
hib 0.00034880638122558594
iting 0.00018465518951416016
▁en 4.76953125
zym 0.00016868114471435547
es 0.11474609375
▁cru 5.12890625
cial 0.0003790855407714844
▁for 1.3291015625
▁tum 0.44091796875
or 0.057159423828125
▁growth 0.56884765625
▁and 0.479248046875
▁pro 2.255859375
gression 0.08148193359375
, 0.01172637939453125
▁Mar 0.57470703125
im 0.0017538070678710938
ast 0.00014913082122802734
at 0.0004875659942626953
▁has 0.7861328125
▁demonstrated 1.490234375
▁an 4.17578125
▁ability 1.701171875
▁to 0.0011148452758789062
▁imp 6.421875
ede 0.03387451171875
▁the 1.056640625
▁spread 0.8037109375
▁of 0.132568359375
▁various 4.29296875
▁cancer 1.447265625
▁types 0.1279296875
. 1.341796875
▁This 3.134765625
▁break 4.25390625
through 0.0003132820129394531
▁has 1.5244140625
▁raised 3.12890625
▁hopes 0.94775390625
▁of 1.9228515625
▁improved 3.85546875
▁patient 0.85205078125
▁out 0.05029296875
comes 6.413459777832031e-05
▁and 0.431884765625
▁a 1.54296875
▁higher 6.47265625
▁quality 1.2939453125
▁of 0.002140045166015625
▁life 0.006977081298828125
▁for 0.67333984375
▁those 0.79443359375
▁affected 1.1142578125
▁by 0.21826171875
▁cancer 0.78955078125
. 0.061187744140625
<0x0A> 0.08013916015625
Des 1.4658203125
p 0.0007524490356445312
ite 2.467632293701172e-05
▁these 1.1484375
▁prom 0.89990234375
ising 3.7670135498046875e-05
▁results 0.71923828125
, 0.006671905517578125
▁British 1.681640625
▁Bi 0.0029163360595703125
ote 0.00017333030700683594
ch 0.0012960433959960938
▁Pl 0.99951171875
c 0.0001837015151977539
▁faces 0.479248046875
▁significant 1.0947265625
▁challeng 0.40185546875
es 1.2874603271484375e-05
▁in 0.67578125
▁transform 5.69921875
ing 4.291534423828125e-05
▁Mar 0.220947265625
im 0.0006251335144042969
ast 0.00011646747589111328
at 9.894371032714844e-05
▁from 2.12109375
▁a 0.19580078125
▁prom 1.3330078125
ising 5.793571472167969e-05
▁drug 1.4013671875
▁candidate 1.2431640625
▁into 0.5830078125
▁a 0.027862548828125
▁world 6.6953125
- 0.191162109375
leading 1.705078125
▁block 2.60546875
b 9.131431579589844e-05
uster 0.00011551380157470703
. 0.458984375
▁One 1.9755859375
▁of 0.431640625
▁the 0.0286102294921875
▁primary 1.8564453125
▁obst 0.68701171875
acles 7.212162017822266e-05
▁lies 2.908203125
▁in 0.0163726806640625
▁obtain 3.02734375
ing 0.00039458274841308594
▁regul 0.2423095703125
atory 7.736682891845703e-05
▁appro 0.00612640380859375
val 4.887580871582031e-06
. 1.98828125
▁The 1.244140625
▁drug 1.0986328125
' 2.73828125
s 4.470348358154297e-05
▁safety 2.673828125
▁profile 1.291015625
▁and 1.4072265625
▁effic 0.85986328125
acy 7.033348083496094e-06
▁data 2.873046875
▁must 0.39794921875
▁with 6.2265625
stand 0.0013408660888671875
▁rig 0.59521484375
orous 0.0009775161743164062
▁scr 0.298583984375
ut 2.1457672119140625e-06
iny 0.0006489753723144531
▁from 0.833984375
▁regul 0.414794921875
atory 0.157958984375
▁bodies 0.93603515625
▁such 1.490234375
▁as 7.224082946777344e-05
▁the 0.00446319580078125
▁Medic 6.828125
ines 0.0007777214050292969
▁and 0.0631103515625
▁Health 0.00034546852111816406
care 0.007232666015625
▁products 0.353759765625
▁Reg 0.0008873939514160156
ul 0.005336761474609375
atory 1.0132789611816406e-05
▁Agency 0.006938934326171875
▁( 0.10687255859375
M 0.0019445419311523438
H 0.0004382133483886719
RA 9.226799011230469e-05
). 1.8583984375
▁While 4.97265625
▁pre 3.1875
cl 0.29833984375
in 1.2040138244628906e-05
ical 3.707408905029297e-05
▁tri 2.263671875
als 2.014636993408203e-05
▁indicate 3.6953125
▁positive 3.263671875
▁results 0.46923828125
, 0.044036865234375
▁further 2.53515625
▁clin 0.71533203125
ical 0.0001544952392578125
▁studies 2.86328125
▁involving 4.6328125
▁a 1.890625
▁larger 0.302978515625
▁pool 4.44140625
▁of 0.0010700225830078125
▁patients 0.2261962890625
▁are 0.4365234375
▁necessary 0.97900390625
. 3.5078125
▁These 3.544921875
▁tri 1.0
als 2.0384788513183594e-05
▁can 2.38671875
▁be 0.65673828125
▁cost 0.77587890625
ly 0.002315521240234375
▁and 0.19140625
▁time 0.205078125
- 0.004425048828125
consum 0.00910186767578125
ing 1.537799835205078e-05
, 0.088623046875
▁which 3.935546875
▁may 1.1533203125
▁h 2.421875
inder 0.0001308917999267578
▁the 0.6416015625
▁drug 0.48583984375
' 0.0144500732421875
s 6.16312026977539e-05
▁progress 1.8447265625
▁towards 1.974609375
▁regul 1.5263671875
atory 7.390975952148438e-05
▁appro 0.00933837890625
val 1.049041748046875e-05
. 0.09075927734375
<0x0A> 0.06463623046875
F 2.642578125
ur 0.0758056640625
ther 7.033348083496094e-06
more 0.3486328125
, 0.00010383129119873047
▁competition 2.576171875
▁within 2.740234375
▁the 0.00403594970703125
▁ph 0.89892578125
arma 0.0006341934204101562
ce 0.00298309326171875
ut 5.960464477539062e-07
ical 3.147125244140625e-05
▁industry 0.0938720703125
▁pos 3.51171875
es 1.9669532775878906e-05
▁a 0.55224609375
▁form 2.375
id 2.0742416381835938e-05
able 1.0013580322265625e-05
▁hur 2.62890625
d 8.344650268554688e-07
le 4.76837158203125e-05
. 0.96435546875
▁Several 2.34765625
▁established 1.529296875
▁players 1.091796875
, 1.412109375
▁armed 9.5234375
▁with 0.0002168416976928711
▁their 4.71875
▁own 0.70263671875
▁cutting 4.69921875
- 0.0006051063537597656
edge 6.389617919921875e-05
▁cancer 0.90625
▁treat 1.4931640625
ments 1.0371208190917969e-05
, 0.036529541015625
▁are 1.099609375
▁v 1.02734375
ying 9.775161743164062e-05
▁for 0.07952880859375
▁domin 2.369140625
ance 0.0004074573516845703
▁in 0.144775390625
▁the 0.314453125
▁market 0.7744140625
. 0.0865478515625
▁British 1.8544921875
▁Bi 0.0030460357666015625
ote 3.9577484130859375e-05
ch 0.0003800392150878906
▁Pl 0.04156494140625
c 5.078315734863281e-05
▁must 0.357421875
▁navigate 1.96484375
▁through 2.84765625
▁this 0.66357421875
▁compet 2.37890625
itive 0.0002994537353515625
▁landscape 0.076904296875
, 1.396484375
▁distingu 5.15625
ishing 3.1828880310058594e-05
▁Mar 1.6708984375
im 0.0012979507446289062
ast 0.00018644332885742188
at 0.0001354217529296875
' 1.8740234375
s 0.0003159046173095703
▁unique 0.276123046875
▁s 2.81640625
elling 2.956390380859375e-05
▁proposition 1.3349609375
▁and 0.479248046875
▁establish 2.74609375
ing 0.00054931640625
▁its 1.3134765625
▁superior 2.966796875
ity 0.049163818359375
▁over 0.372802734375
▁existing 1.359375
▁alternatives 2.095703125
. 0.0164642333984375
▁This 2.107421875
▁requires 0.8994140625
▁substantial 2.736328125
▁invest 0.278564453125
ments 2.00390625
▁in 0.078125
▁market 0.57177734375
ing 0.0017337799072265625
, 1.1572265625
▁clin 3.904296875
ical 0.0003037452697753906
▁tri 0.259033203125
als 1.1324882507324219e-05
, 0.03338623046875
▁and 0.029449462890625
▁infrastr 4.4609375
ucture 0.019622802734375
▁to 2.4375
▁effectively 3.41015625
▁promote 2.05078125
▁and 1.4921875
▁dist 0.70849609375
ribute 1.3113021850585938e-05
▁the 0.0240936279296875
▁drug 0.0261993408203125
. 0.414306640625
<0x0A> 0.1251220703125
Add 4.04296875
itionally 0.044952392578125
, 5.710124969482422e-05
▁financial 4.24609375
▁consider 1.990234375
ations 2.2649765014648438e-06
▁represent 3.97265625
▁another 1.6826171875
▁challenge 3.271484375
▁for 1.3759765625
▁British 0.26220703125
▁Bi 0.0017337799072265625
ote 8.106231689453125e-06
ch 0.00012791156768798828
▁Pl 0.0186309814453125
c 5.5789947509765625e-05
. 0.05548095703125
▁The 1.265625
▁costs 4.0234375
▁associated 0.53759765625
▁with 4.7326087951660156e-05
▁clin 1.6435546875
ical 6.866455078125e-05
▁tri 0.0401611328125
als 1.1920928955078125e-06
, 0.19970703125
▁manufact 1.8056640625
uring 0.0008192062377929688
, 0.0948486328125
▁market 2.826171875
ing 0.003543853759765625
, 0.0272674560546875
▁and 0.0106353759765625
▁obtain 6.01953125
ing 8.20159912109375e-05
▁regul 0.0106964111328125
atory 9.179115295410156e-06
▁appro 0.00115966796875
val 8.940696716308594e-06
s 4.57421875
▁demand 8.859375
▁substantial 0.90478515625
▁fund 1.7919921875
ing 0.0020999908447265625
. 0.1983642578125
▁In 3.6171875
vest 0.31884765625
ments 4.5625
▁must 2.19921875
▁be 0.250244140625
▁secured 2.85546875
▁to 1.1181640625
▁meet 4.265625
▁these 0.12371826171875
▁dem 1.5185546875
ands 0.0001125335693359375
, 0.471923828125
▁either 4.45703125
▁through 0.10845947265625
▁partners 2.3515625
hips 0.006824493408203125
, 0.90625
▁lic 3.83984375
ens 0.016082763671875
ing 1.823902130126953e-05
▁agre 0.4716796875
ements 2.384185791015625e-07
, 0.013824462890625
▁or 0.04852294921875
▁other 4.10546875
▁financial 2.59375
▁arrang 0.8232421875
ements 4.0531158447265625e-06
. 0.039154052734375
▁Sec 3.068359375
uring 0.0014410018920898438
▁sufficient 1.62890625
▁fund 0.48779296875
ing 0.0001195669174194336
▁is 1.6181640625
▁essential 1.8662109375
▁to 0.7412109375
▁sust 4.06640625
ain 0.61181640625
▁the 0.405517578125
▁drug 0.88818359375
' 0.045623779296875
s 8.893013000488281e-05
▁development 0.23095703125
▁and 0.43798828125
▁reach 4.515625
▁the 1.4716796875
▁market 0.86669921875
▁effectively 4.49609375
. 0.056396484375
<0x0A> 0.0692138671875
Des 1.1416015625
p 1.4543533325195312e-05
ite 1.3232231140136719e-05
▁these 0.12017822265625
▁hur 1.46875
d 1.1920928955078125e-06
les 8.702278137207031e-06
, 0.0019378662109375
▁British 0.12890625
▁Bi 0.0012350082397460938
ote 8.821487426757812e-06
ch 0.00011909008026123047
▁Pl 0.00460052490234375
c 2.014636993408203e-05
▁remains 0.2254638671875
▁optim 0.50439453125
istic 2.5987625122070312e-05
▁about 0.1436767578125
▁Mar 1.1005859375
im 0.0006175041198730469
ast 6.318092346191406e-05
at 0.0001494884490966797
' 0.005558013916015625
s 2.0742416381835938e-05
▁future 2.02734375
▁potential 2.447265625
. 0.053619384765625
▁The 0.31982421875
▁company 0.29248046875
' 1.25390625
s 6.091594696044922e-05
▁commit 1.9541015625
ment 3.159046173095703e-05
▁to 0.01410675048828125
▁research 2.28515625
▁and 0.04608154296875
▁development 0.127197265625
, 1.0986328125
▁couple 1.220703125
d 4.76837158203125e-07
▁with 2.396106719970703e-05
▁early 7.578125
▁positive 3.119140625
▁indic 4.2890625
ations 0.168212890625
, 0.93603515625
▁fost 6.23046875
ers 0.1102294921875
▁hope 0.94775390625
▁for 0.370361328125
▁a 0.71826171875
▁successful 1.7568359375
▁outcome 1.412109375
. 0.023590087890625
▁However 2.3671875
, 2.1696090698242188e-05
▁a 3.783203125
▁considerable 4.28515625
▁amount 0.492431640625
▁of 0.002246856689453125
▁time 1.5029296875
, 0.888671875
▁dedic 5.7890625
ation 2.110004425048828e-05
, 0.0023956298828125
▁and 0.01873779296875
▁resources 1.0654296875
▁will 1.7158203125
▁determine 10.515625
▁Mar 1.5751953125
im 0.0009579658508300781
ast 0.0001901388168334961
at 0.00021398067474365234
' 0.00240325927734375
s 5.3882598876953125e-05
▁journey 3.0625
▁from 2.162109375
▁an 3.58984375
▁exc 2.42578125
iting 1.3947486877441406e-05
▁prospect 2.013671875
▁to 0.0303802490234375
▁a 0.0333251953125
▁break 4.5234375
through 0.01143646240234375
▁block 1.2177734375
b 2.753734588623047e-05
uster 3.552436828613281e-05
▁drug 1.6630859375
. 0.04632568359375
<0x0A> 0.5263671875
In 0.9443359375
▁conclusion 0.15234375
, 7.319450378417969e-05
▁British 0.5869140625
▁Bi 0.001491546630859375
ote 1.8715858459472656e-05
ch 0.00027370452880859375
▁Pl 0.00621795654296875
c 3.4689903259277344e-05
' 0.378173828125
s 0.00019919872283935547
▁cancer 4.41015625
▁drug 0.07452392578125
▁Mar 1.51171875
im 0.00031304359436035156
ast 6.35385513305664e-05
at 5.4955482482910156e-05
▁has 2.501953125
▁shown 1.7373046875
▁trem 2.947265625
end 8.344650268554688e-07
ous 4.9114227294921875e-05
▁promise 0.29296875
▁in 0.454833984375
▁early 1.626953125
▁tri 2.787109375
als 1.1682510375976562e-05
. 1.1484375
▁However 0.7607421875
, 4.76837158203125e-05
▁regul 4.26953125
atory 0.00012826919555664062
▁appro 0.078369140625
val 4.649162292480469e-06
, 0.09295654296875
▁the 6.08984375
▁compet 1.142578125
itive 0.0012340545654296875
▁landscape 0.454345703125
, 0.01514434814453125
▁and 0.098876953125
▁the 4.28125
▁need 1.9287109375
▁for 0.01715087890625
▁substantial 0.88916015625
▁fund 0.853515625
ing 0.00021851062774658203
▁are 3.19140625
▁significant 0.467529296875
▁obst 1.3994140625
acles 5.5670738220214844e-05
▁that 1.01953125
▁must 0.578125
▁be 0.0033168792724609375
▁overcome 0.341552734375
▁to 0.974609375
▁bring 2.2421875
▁Mar 3.08203125
im 0.0004253387451171875
ast 3.349781036376953e-05
at 9.799003601074219e-05
▁to 0.0294189453125
▁market 0.82861328125
▁successfully 4.17578125
. 0.0171051025390625
▁The 1.904296875
▁journey 4.02734375
▁to 1.8271484375
▁becoming 2.3828125
▁a 0.00917816162109375
▁block 0.1580810546875
b 3.2782554626464844e-05
uster 3.230571746826172e-05
▁drug 0.10577392578125
▁may 2.875
▁be 0.373291015625
▁challeng 1.330078125
ing 5.0187110900878906e-05
, 0.048126220703125
▁but 0.05731201171875
▁the 1.55859375
▁potential 0.490478515625
▁benefits 0.85986328125
▁for 0.73876953125
▁cancer 1.212890625
▁patients 0.0110321044921875
▁make 2.037109375
▁it 0.32421875
▁a 1.009765625
▁journey 3.013671875
▁worth 0.051788330078125
▁purs 1.724609375
uing 9.751319885253906e-05
. 0.021148681640625
